Text Size

Author’s reply to: “concerns over: Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease”

Leonardi A., Van Setten G., Amrane M., Ismail D., Garrigue J.-S., Figueiredo F.C., Baudouin C.


  • 2017
  • European Journal of Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy; St. Eriks Eye Hospital, Stockholm, Sweden; Santen SAS, Evry, France; Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, United Kingdom; Quinze-Vingts National Ophthalmology Hospital, Paris, France; UPMC University, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris 6, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France

Related Publications

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.


NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis

Leonardi A.; Pisella P.-J.; Benítez-del-Castillo J.M.; Amrane M.; Ismail D.; Doan S.; Bremond-Gignac D.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022